Introduction
In 1978, Brzosko treated children with HBsAg positive chronic active hepatitis by administering Bacillus Calmette Guerin (BCG), a substance extracted from the Bovine tubercle bacillus, and found that HBsAg disappeared in about 30% of the cases. Thereafter, Bassendine" reported that immunotherapy with BCG was effective in 3 out of 9 patients with total elimination of HBV associated antigens or decreased viral replication accompanied by decreased inflammatory activity. 
Changes in serum transaminase levels
The changes in the SGOT levels of the 14 patients in the HBeAg positive group over the observation period are shown in Fig. 3 . A transient rise in SGOT was seen 3 months after the beginning of treatment in two patients and 6 months after the beginning of treatment in 48(198) ents. In a Japanese report, the annual rate of patients becoming negative for HBeAg was calculated to be 9.6%. Compared with data for the natural course of the disease, the seroconversion rate with SSM is superior and the median time between the start of therapy and the disappearance of HBeAg (10.0 months) is shorter, suggesting that the seroconversion or disappearance of HBeAg in the present study was related to treatment with SSM.
The rate of HBeAg seroconversion after treatment was reported to be 27.3%o with prednisolone and/or azathiopurine, 75% with levamizol, 18.2% with Ara-A, 33.3% with transfer factor, 4.5% with interferon and 22.2% with OK-432. The rate with SSM (28.6%) is comparable to these results. In addition to HBeAg seroconversion, the titer of anti-HBc tended to decrease after the treatment with SSM, suggesting that SSM also has further beneficial effects with regard to HBV replication, though these were not always pronounced and further studies with more cases are requested.
The disappearance of HBsAg was not seen in any of the patients treated with SSM.
On the other hand, anti-HBs, the neutralized antibody for HBV infection, developed in four (15.4%) out of the 26 patients in the present study. It is difficult to conclude that the appearance of anti-HBs resulted from the effects of SSM, since the anti-HBs level before treatment in some of the patients had been measured according to the PHA method and not by the RIA method. Accordingly, the possibility remains that anti-HBs would have been positive even before the treatment in these patients if it had been measured by RIA.
A reduction in DNAp is considered a favorable effect in the treatment for HBV infection, since it indicates a decrease in viral replication. In the present study DNAp tended to decrease after at least twelve months of treatment. However, a transient rise before this reduction was also observed, as shown in the typical case outlined in Fig. 2 . On these changes in DNAp, no clear explanation is yet possible. As far as immunomodulating therapy is concerned, no data is as yet available on the effects on DNAp.
A transient rise in SGOT and SGPT coincident with the disappearance of HBeAg was observed 3 or 6months after treatment with SSM in.8 patients out of the HBeAg positive group. It was followed by a significant fall from pretreatment levels after 9 months. Similar results have been reported elsewhere, where the termination of therapy with prednisolone was followed by a transient rise in serum asparate transaminase, coincident with disappearance of HBeAg and seroconversion. Furthermore, some reports have disclosed that a transient rise in transaminases is followed by HBeAg seroconversion in the natural course of the disease. These results allow. us to consider the possibility that a transient rise in transaminases may be a condition for the seroconversion of HBeAg. These events may represent development of a state of enhanced immunity to the virus.
SSM is almost free from any side effects. This is the main advantage of SSM compared to other treatments, including corticosteroid and antiviral drugs. (Received for Publication, October 22, 1983) 
